Evolving ideas on non-alcoholic fatty liver disease: from risk to catastrophe


  • Yu. M. Stepanov National Academy of Medical Sciences of Ukraine”, Dnipro,
  • O. Yu. Filippova SI “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro,




non-alcoholic fatty liver disease, fatty liver, steatohepatitis, clinic, diagnosis, treatment, comorbidity



The aim of the work is to study the development of non-alcoholic fatty liver disease (NAFLD) accompanied by changes in the clinical course and general transformation of diagnostic and therapeutic approaches to a patient with comorbid conditions.

Materials and methods. A retrospective and prospective analysis of the specialized literature and research on NAFLD associated with comorbid clinical conditions was carried out.

Results. The review of the scientific literature provides data on the development of NAFLD associated with comorbidity, the results of clinical studies, as well as own observations. The main causes and risk factors, pathogenesis, prevalence and course of NAFLD, which is a hepatic manifestation of metabolic syndrome, are discussed. The criteria for NAFLD diagnosis, diagnostic capabilities of various invasive and non-invasive methods, and modern approaches to the management of patients are presented. It has been shown that modern NAFLD treatment should take into account all existing risk factors including lifestyle modification, implications for metabolic syndrome components, hepatoprotective therapy, and correction of the intestinal microbiota.

Conclusions. NAFLD in modern conditions is one of the most common diseases among the Ukrainian population in the overall structure of the internal organ pathology. Insufficient information on the features of NAFLD comorbid course limits the possibilities of diagnosis and treatment for this category of patients. Thus, the history of the development, progression and treatment of NAFLD comorbid course is constantly being improved.


Bazylevych, A. Ya. (2015). Nealkoholnyi steatohepatyt yak novyi faktor rozvytku ishemichnoi khvoroby sertsia [Non-alcoholic steatohepatitis as a new factor of developing ischaemic heart disease]. ScienceRise, (10), 171-175. https://doi.org/10.15587/2313-8416.2015.52369 [in Ukrainian].

Nabieva, D. A. (2017). Immunologicheskie mekhanizmy razvitiya nealkogol'noi zhirovoi bolezni pecheni u bol'nykh podagroi i psevdopodagroi: obzor literatury [Immunological mechanisms for the development of nonalcoholic fatty liver disease in patients with gout and pseudogout: a review of literature]. Nauchno-prakticheskaya revmatologiya, 55(5), 560-565. https://doi.org/10.14412/1995-4484-2017-560-565 [in Russian].

Pal'gova, L. K. (2014). Geneticheskie faktory patogeneza nealkogol'noi zhirovoi bolezni pecheni: fundamental'nye i prikladnye aspekty. Est' li puti resheniya? [Genetic factors in the pathogenesis of non-alcoholic fatty liver disease: fundamental and applied aspects. Are there any solutions?]. Consilium Medicum. Gastroenterologiya, (1),18-23. [in Russian].

Rozumbaeva, L. P., Kozlova, I. V., Bykova, A. P., Safonova, M. V., & Pakhomova, A. L. (2014). Patologiya gepatobiliarnoy sistemy i psoriaz: vzaimosvyazi i vzaimovliyaniya [Psoriasis and pathology of the hepatobiliary system: the relationship and mutual influence]. Sovremennye problemy nauki i obrazovaniya, (4). [in Russian]. http://www.science-education.ru/ru/article/view?id=14105.

Stepanov, Yu. M., & Filippova, A. Yu. (2006). Klinicheskie osobennosti techeniya nealkogol'nogo steatogepatita v zavisimosti ot soputstvuyushchikh zabolevanii [Peculiarities of the clinical course of nonxalcoholic steatohepatitis depending on concomitant diseases]. Suchasna hastroenterolohiia, (3), 4-7. http://www.vitapol.com.ua/user_files/pdfs/gastro/337868311858671_15062009105858.pdf. [in Russian].

Stepanov, Yu. M., & Filippova, О. Yu. (2016). Osoblyvosti zmin pokaznykiv T- ta V-klitynnoho imunitetu zalezhno vid indeksu masy tila u patsiientiv z nealkoholnoiu zhyrovoiu khvoroboiu pechinky u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [The features of the changes of T- and B-cell immunity depending on the body mass index in the patients with the nonalcoholic fatty liver disease in combination with the obesity and the pathology of biliary tract]. Ukrainskyi terapevtychnyi zhurnal, (4), 46-54. http://www.vitapol.com.ua/user_files/pdfs/utj/utj51i08iutj4-16.pdf. [in Ukrainian].

Stepanov, Yu. M., & Filippova, A. Yu. (2017). Morfolohichni osnovy otsinky steatozu, steatohepatytu ta fibrozu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky v poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [Morphological basis for the assessment of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease associated with obesity and pathology of the biliary tract]. Hastroenterologia, 51(3), 196-204. https://doi.org/10.22141/2308-2097.51.3.2017.112636 [in Ukrainian].

Filippova, A. Yu. (2016). Nadlyshkova masa tila i ozhyrinnia yak prychyna prohresuvannia endohennoi intoksykatsii u patsiientiv z nealkoholnoiu zhyrovoiu khvoroboiu pechinky [Excessive body mass and obesity as a cause of progression of endogenous intoxication in patients with non-alcoholic fatty liver disease]. Zaporozhye medical journal, (3), 63-66. https://doi.org/10.14739/2310-1210.2016.3.76985 [in Ukrainian].

Filippova, A. Yu. (2016). Klinichna kharakterystyka khvorykh na steatoz pechinky ta nealkoholnyi steatohepatyt u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu zalezhno vid indeksu masy tila [Clinical characteristics of patients with hepatic steatosis and non-alcoholic steatohepatitis, combined with obesity and disorders of the biliary tract, depending on the body mass index]. Medychni perspektyvy, 21(1), 70-79. [in Ukrainian].

Filippova, A. Yu. (2017). Dynamika antropometrychnykh i biokhimichnykh pokaznykiv pid vplyvom riznykh skhem likuvannia u khvorykh na nealkoholnu zhyrovu khvorobu pechinky u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [Dynamics of anthropometric and biochemical parameters under the influence of different treatment regimens in patients with non-alcoholic fatty liver disease in combination with obesity and pathology of the biliary tract]. Likarska sprava, (5-6), 54-61. [in Ukrainian].

Bao, Y. (Bao, Y.). The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases. Zhonghua gan zang bing za zhi, 25(7), 553-556. https://doi.org/10.3760/cma.j.issn.1007-3418.2017.07.018 [in Chinese].

Cani, P. D., Everard, A., & Duparc, T. (2013). Gut microbiota, enteroendocrine functions and metabolism. Current Opinion in Pharmacology, 13(6), 935-940. https://doi.org/10.1016/j.coph.2013.09.008

Della Corte, C., Mazzotta, A. R., & Nobili, V. (2016). Fatty liver disease and obesity in youth. Current Opinion in Endocrinology & Diabetes and Obesity, 23(1), 66-71. https://doi.org/10.1097/med.0000000000000221

Grechanyk, M. M., Grechanyk, N. M., Filippova, A. J., & Kuryata, A. V. (2016). Endothelial dysfunction, level of leptin and body mass index in patient with coronary heart disease with preserved systolic function in combination with hepatic steatosis. European Journal of Heart Failure, 18(Suppl. 1), 273. https://onlinelibrary.wiley.com/toc/18790844/18/S1

Filippova, O. Yu. (2016). Imbalance of the Humoral Component of the Immune System as a Basis for the Progression of Non-Alcoholic Fatty Liver Disease in Patients with Obesity and Concomitant Biliary Tract Pathology. Arkhiv klinichnoi medytsyny, (2), 43-47. https://doi.org/10.21802/acm.2016.2.9

Grechanyk, N., Filippova, A., & Kuryata, A. (2016). Endotelial dysfunction, blood lipid spectrum, level of leptin and mass of body in patient with coronary heart disease in combination with hepatic steatosis. Atherosclerosis, 252, Article e161. https://doi.org/10.1016/j.atherosclerosis.2016.07.774

Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings, 55(7), 434-438.

Manne, V., Handa, P., & Kowdley, K. V. (2018). Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 22(1), 23-37. https://doi.org/10.1016/j.cld.2017.08.007

Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2015). Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 47(3), 181-190. https://doi.org/10.1016/j.dld.2014.09.020

L’Hermitte, A., Pham, S., Cadoux, M., & Couty, J.-P. (2016). Non alcoholic-fatty liver disease causes selective CD4+ T lymphocytes loss and promotes hepatocarcinogenesis. Medecine Sciences (Paris), 32(11), 1023-1026. https://doi.org/10.1051/medsci/20163211021 [in French].

Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017). Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxidants & Redox Signaling, 26(10), 519-541. https://doi.org/10.1089/ars.2016.6776

Ray, I., Bhattacharya, A., & De, R. K. (2017). OCDD: an obesity and co-morbid disease database. BioData Mining, 10, Article 33. https://doi.org/10.1186/s13040-017-0153-5

Lee, S.-W., Lee, T.-Y., Yang, S.-S., Tung, C.-F., Yeh, H.-Z., & Chang, C.-S. (2018). Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary & Pancreatic Diseases International, 17(1), 45-48. https://doi.org/10.1016/j.hbpd.2018.01.007

Sookoian, S., & Pirola, C. J. (2011). Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology, 53(6), 1883-1894. https://doi.org/10.1002/hep.24283

Reardon, J., Hussaini, T., Alsahafi, M., Azalgara, V. M., Erb, S. R., Partovi, N., & Yoshida, E. M. (2016). Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review. Journal of Clinical and Translational Hepatology, 4(3), 192-205. https://doi.org/10.14218/jcth.2016.00023

Valenti, L., Alisi, A., & Nobili, V. (2012). I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology, 56(2), 1883-1889.

Westwater, J. O., & Fainer, D. (1958). Liver impairment in the obese. Gastroenterology, 34(4), 686-693.

World Health Organization. (‎2020, March 3)‎. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/.

Zelman, S. (1952). The liver in obesity. Archives of Internal Medicine, 90(2), 141-156. https://doi.org/10.1001/archinte.1952.00240080007002

Zhang, Q. Q., & Lu, L. G. (2015). Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. Journal of Clinical and Translational Hepatology, 3(1), 78-84. https://doi.org/10.14218/jcth.2014.00037

How to Cite

Stepanov YM, Filippova OY. Evolving ideas on non-alcoholic fatty liver disease: from risk to catastrophe. Zaporozhye Medical Journal [Internet]. 2020Apr.13 [cited 2024Jul.17];22(2). Available from: http://zmj.zsmu.edu.ua/article/view/200637